Previous studies have reported a higher incidence of HER2 overexpression in IBC cases (52%) [21, 22], though neither study reported HER2-positive status as a significant prognostic factor for survival in IBC patients. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.